BCT.TO - BriaCell Therapeutics Corp.

Toronto - Toronto Real Time Price. Currency in CAD

BriaCell Therapeutics Corp.

Bellevue Centre
Suite 300 235 West 15th Street
West Vancouver, BC V7T 2X1


Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. William V. Williams M.D.CEO, Pres & Director710.99kN/A1957
Mr. Gadi Levin B.Com., C.A., CPA, M.B.A., MBACFO & Corp. Sec.247.09kN/A1973
Dr. Miguel A. Lopez-LagoChief Scientific Officer246.62kN/A1969
Dr. Giuseppe Del Priore M.D., M.P.H., MPHChief Medical Officer438.86kN/A1962
Dr. Charles Louis Wiseman FACP, M.D.Founder, Principal Research Advisor & Member of Scientific Advisory BoardN/AN/A1946
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Corporate Governance

BriaCell Therapeutics Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.